Elotuzumab (Empliciti)
On February 8th, 2016
On November 30, 2015, the U. S. Food and Drug Administration approved elotuzumab (EMPLICITI, Bristol-Myers Squibb Company) in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.
Full prescribing information is available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761035s000lbl.pdf
On November 30, 2015, the U. S. Food and Drug Administration approved elotuzumab (EMPLICITI, Bristol-Myers Squibb Company) in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.
Full prescribing information is available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761035s000lbl.pdf
No comments have been posted yet.